Pharmaceuticals

Antibody Fragments Market Anticipated to Record Steady Gains, Advancing to $17.56 Billion by 2030

February 12, 2026February 12, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the antibody fragments market from 2026–2035 with trusted insights from The Business Research Company

What was the valuation of the Antibody Fragments Market in 2026, and what figure is it projected to hit by 2030?

The antibody fragments market has experienced substantial growth in recent years. Its value is set to increase from $11.26 billion in 2025 to $12.31 billion in 2026, progressing at a compound annual growth rate (CAGR) of 9.3%. The expansion observed historically can be credited to the progression of monoclonal antibody technologies, the clinical achievements of antibody-derived treatments, a rise in cancer biologics research, the broadened application of diagnostic antibodies, and increased funding in biologics research and development.

The antibody fragments market is set for robust expansion over the next few years, with its valuation expected to reach $17.56 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.3%. This anticipated growth during the forecast period is primarily driven by the advancements in targeted cancer therapies, the increasing development of antibody fragment pipelines, a heightened demand for precision biologics, the expanding application in companion diagnostics, and continuous innovation in recombinant antibody engineering. Major trends foreseen for this period include the growing acceptance of fragment-based biologics, their broadened use in oncology and targeted therapies, an escalating demand for high-penetration antibody formats, the diversification of diagnostic applications, and an increased emphasis on treatments designed to minimize immunogenicity.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23307&type=smp

Which Drivers Are Affecting Market Participation In The Antibody Fragments Market?

The anticipated expansion of the antibody fragments market is driven by the rising occurrence of target diseases. These are defined as particular illnesses or health conditions that medical interventions, treatments, or research efforts aim to prevent, control, or heal. Prominent examples of such target diseases encompass cancer, infectious diseases, and bacterial infections. This growing prevalence largely stems from detrimental lifestyle choices and environmental pollution, which compromise the body’s immune system, resulting in chronic ailments. Antibody fragments offer highly specific, focused, and adaptable solutions for treating numerous conditions, frequently presenting fewer adverse effects than conventional treatments. Their inherent capacity for customization and engineering to target specific ailments positions them as an increasingly vital asset in contemporary medicine. As an illustration, a report released in January 2025 by the American Cancer Society, a US non-profit, forecasts 2,041,910 new cancer cases and 618,120 fatalities in the United States during 2025. This represents an increase from 2,001,140 new cases and 611,720 deaths recorded in 2024. Consequently, the rising occurrence of target diseases acts as a significant impetus for the expansion of the antibody fragments market.

What Segment Classifications Make Up The Antibody Fragments Market?

The antibody fragments market covered in this report is segmented –

1) By Type: F(ab) Fragments, F(ab’)2 Fragments, Single-Chain Variable Fragments (scFvs), Single Domain Antibody Fragments (sdAbs), Other Types

2) By Specificity: Monoclonal Antibody, Polyclonal Antibody

3) By Delivery Method: Intravenous (IV), Subcutaneous (SC)

4) By Application: Cancer, Immunodeficiencies, Other Applications

5) By End User: Pharmaceutical Companies, Biotechnology Companies, Research Institutions, Diagnostic Laboratories, Contract Research Organizations (CROs)

Subsegments:

1) By F(ab) Fragments: Recombinant F(ab) Fragments, Enzymatically Derived F(ab) Fragments

2) By F(ab’)2 Fragments: Pepsin-Derived F(ab’)2 Fragments, Recombinant F(ab’)2 Fragments

3) By Single-Chain Variable Fragments (scFvs): Bacterial-Produced Single-Chain Variable Fragments (scFvs), Mammalian Cell-Produced Single-Chain Variable Fragments (scFvs), Yeast-Produced Single-Chain Variable Fragments (scFvs)

4) By Single Domain Antibody Fragments (sdAbs): Camelid-Derived Single Domain Antibody Fragments (sdAbs), Shark-Derived Single Domain Antibody Fragments (sdAbs), Synthetic Single Domain Antibody Fragments (sdAbs)

5) By Other Types: Bispecific Antibody Fragments, Multispecific Antibody Fragments, Fusion Protein Antibody Fragments

Which Trends Are Influencing The Development Of The Antibody Fragments Market?

Leading companies in the antibody fragments market are primarily focused on conducting clinical trials to develop innovative products, such as human VH antibody fragments, aiming to boost targeted therapy effectiveness and lessen immunogenicity when treating cancers, autoimmune disorders, and infectious diseases. A human VH antibody fragment is defined as the variable domain of the heavy chain of a human antibody, capable of independently binding to antigens. It contributes to forming antibody fragments by serving as the essential antigen-binding region, frequently utilized alone or fused with other molecules to produce small, stable, high-affinity therapeutic or diagnostic antibodies. For instance, in May 2024, Zai Lab Limited, a pharmaceutical company based in China, initiated a global Phase 2 clinical trial to evaluate the efficacy and safety of ZL-1102. ZL-1102 is a novel human VH antibody fragment (Humabody) that targets IL-17. It is being developed as a topical therapy for mild-to-moderate chronic plaque psoriasis to enhance treatment precision while minimizing systemic side effects and immunogenic responses.

Which Major Firms Are Strengthening Their Position In The Antibody Fragments Market?

Major companies operating in the antibody fragments market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A., AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., UCB S.A., Bio-Rad Laboratories Inc., Genmab A/S, WuXi Biologics Co. Ltd., Abcam plc, MacroGenics Inc., Harbour BioMed, Creative Biolabs Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/antibody-fragments-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Antibody Fragments Market?

North America was the largest region in the antibody fragments market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibody fragments market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Antibody Fragments Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23307&type=smp

Browse Through More Reports Similar to the Global Antibody Fragments Market 2026, By The Business Research Company

Antibody Discovery Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibody-discovery-global-market-report

Polyclonal Antibodies Market Report 2026

https://www.thebusinessresearchcompany.com/report/polyclonal-antibodies-global-market-report

Research Antibodie And Reagent Market Report 2026

https://www.thebusinessresearchcompany.com/report/research-antibodie-and-reagent-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795